XTX Topco Ltd Buys 3,295 Shares of Repligen Corporation (NASDAQ:RGEN)

XTX Topco Ltd grew its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 34.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,935 shares of the biotechnology company’s stock after acquiring an additional 3,295 shares during the quarter. XTX Topco Ltd’s holdings in Repligen were worth $1,646,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Utah Retirement Systems increased its position in shares of Repligen by 1.1% during the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company’s stock valued at $1,338,000 after purchasing an additional 100 shares during the last quarter. State of Michigan Retirement System grew its position in Repligen by 0.8% during the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock valued at $1,585,000 after buying an additional 100 shares during the period. Louisiana State Employees Retirement System increased its holdings in Repligen by 0.7% during the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock valued at $1,858,000 after buying an additional 100 shares during the last quarter. Peapack Gladstone Financial Corp increased its holdings in Repligen by 5.2% during the fourth quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 103 shares during the last quarter. Finally, Signaturefd LLC raised its position in Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 128 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

NASDAQ:RGEN opened at $117.07 on Friday. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The stock has a market cap of $6.58 billion, a PE ratio of -468.26, a P/E/G ratio of 2.27 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. The stock has a 50 day moving average price of $123.46 and a 200 day moving average price of $136.78.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.65%. The firm had revenue of $182.37 million for the quarter, compared to analysts’ expectations of $174.62 million. During the same period in the previous year, the firm posted $0.40 EPS. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. Equities research analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analyst Ratings Changes

RGEN has been the topic of several recent research reports. Royal Bank Of Canada raised their price objective on Repligen from $193.00 to $204.00 and gave the stock an “outperform” rating in a research note on Wednesday. JPMorgan Chase & Co. decreased their target price on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. Barclays assumed coverage on shares of Repligen in a report on Tuesday, June 24th. They set an “overweight” rating and a $150.00 price target on the stock. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research note on Sunday, June 29th. Finally, Wolfe Research upgraded shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective on the stock in a research report on Tuesday, April 29th. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and an average price target of $169.45.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.